vs
CSW INDUSTRIALS, INC.（CSW）とLantheus Holdings, Inc.（LNTH）の財務データ比較。上の社名をクリックして会社を切り替えられます
Lantheus Holdings, Inc.の直近四半期売上が大きい（$406.8M vs $233.0M、CSW INDUSTRIALS, INC.の約1.7倍）。Lantheus Holdings, Inc.の純利益率が高く（13.3% vs 4.4%、差は8.9%）。CSW INDUSTRIALS, INC.の前年同期比売上増加率が高い（20.3% vs 4.0%）。Lantheus Holdings, Inc.の直近四半期フリーキャッシュフローが多い（$81.4M vs $22.7M）。過去8四半期でCSW INDUSTRIALS, INC.の売上複合成長率が高い（5.1% vs 4.9%）
ランティウス・ホールディングスはグローバルな医療企業で、革新的な診断用造影剤や関連ソリューションの開発・製造・販売を事業の核としています。製品は腫瘍学、循環器学、泌尿器学などの分野に対応し、北米を中心に世界の主要市場で事業を展開しています。
CSW vs LNTH — 直接比較
売上が大きい
LNTH
1.7倍大きい
$233.0M
売上成長率が高い
CSW
+16.3%の差
4.0%
純利益率が高い
LNTH
純利益率が8.9%高い
4.4%
フリーキャッシュフローが多い
LNTH
FCF $58.7M多い
$22.7M
2年売上CAGRが高い
CSW
2年複合成長率
4.9%
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $233.0M | $406.8M |
| 純利益 | $10.3M | $54.1M |
| 粗利率 | 39.7% | 59.2% |
| 営業利益率 | 7.4% | 19.0% |
| 純利益率 | 4.4% | 13.3% |
| 売上前年比 | 20.3% | 4.0% |
| 純利益前年比 | -61.9% | 558.8% |
| EPS（希薄化後） | $0.62 | $0.86 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
売上CSWLNTH
| Q4 25 | $233.0M | $406.8M | ||
| Q3 25 | $277.0M | $384.0M | ||
| Q2 25 | $263.6M | $378.0M | ||
| Q1 25 | $230.5M | $372.8M | ||
| Q4 24 | $193.6M | $391.1M | ||
| Q3 24 | $227.9M | $378.7M | ||
| Q2 24 | $226.2M | $394.1M | ||
| Q1 24 | $210.9M | $370.0M |
純利益CSWLNTH
| Q4 25 | $10.3M | $54.1M | ||
| Q3 25 | $40.7M | $27.8M | ||
| Q2 25 | $40.9M | $78.8M | ||
| Q1 25 | $35.1M | $72.9M | ||
| Q4 24 | $26.9M | $-11.8M | ||
| Q3 24 | $36.1M | $131.1M | ||
| Q2 24 | $38.6M | $62.1M | ||
| Q1 24 | $31.8M | $131.1M |
粗利率CSWLNTH
| Q4 25 | 39.7% | 59.2% | ||
| Q3 25 | 43.0% | 57.9% | ||
| Q2 25 | 43.8% | 63.8% | ||
| Q1 25 | 44.2% | 63.8% | ||
| Q4 24 | 41.4% | 63.5% | ||
| Q3 24 | 45.6% | 63.9% | ||
| Q2 24 | 47.5% | 64.9% | ||
| Q1 24 | 44.4% | 65.4% |
営業利益率CSWLNTH
| Q4 25 | 7.4% | 19.0% | ||
| Q3 25 | 20.5% | 11.4% | ||
| Q2 25 | 20.8% | 23.3% | ||
| Q1 25 | 19.5% | 27.4% | ||
| Q4 24 | 15.3% | 29.1% | ||
| Q3 24 | 22.6% | 35.3% | ||
| Q2 24 | 24.3% | 26.1% | ||
| Q1 24 | 21.0% | 28.8% |
純利益率CSWLNTH
| Q4 25 | 4.4% | 13.3% | ||
| Q3 25 | 14.7% | 7.2% | ||
| Q2 25 | 15.5% | 20.8% | ||
| Q1 25 | 15.2% | 19.6% | ||
| Q4 24 | 13.9% | -3.0% | ||
| Q3 24 | 15.8% | 34.6% | ||
| Q2 24 | 17.1% | 15.8% | ||
| Q1 24 | 15.1% | 35.4% |
EPS（希薄化後）CSWLNTH
| Q4 25 | $0.62 | $0.86 | ||
| Q3 25 | $2.41 | $0.41 | ||
| Q2 25 | $2.43 | $1.12 | ||
| Q1 25 | $2.05 | $1.02 | ||
| Q4 24 | $1.60 | $-0.18 | ||
| Q3 24 | $2.26 | $1.79 | ||
| Q2 24 | $2.47 | $0.88 | ||
| Q1 24 | $2.03 | $1.87 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $40.2M | $359.1M |
| 総負債低いほど良い | — | $568.7M |
| 株主資本純資産 | $1.1B | $1.1B |
| 総資産 | $2.3B | $2.2B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.52× |
8四半期トレンド — 暦四半期で整列
現金・短期投資CSWLNTH
| Q4 25 | $40.2M | $359.1M | ||
| Q3 25 | $31.5M | $382.0M | ||
| Q2 25 | $38.0M | $695.6M | ||
| Q1 25 | $225.8M | $938.5M | ||
| Q4 24 | $213.8M | $912.8M | ||
| Q3 24 | $273.2M | $866.4M | ||
| Q2 24 | $18.9M | $757.0M | ||
| Q1 24 | $22.2M | $718.3M |
総負債CSWLNTH
| Q4 25 | — | $568.7M | ||
| Q3 25 | — | $567.9M | ||
| Q2 25 | — | $566.8M | ||
| Q1 25 | $800.1M | $566.1M | ||
| Q4 24 | — | $565.3M | ||
| Q3 24 | — | $613.0K | ||
| Q2 24 | — | $563.2M | ||
| Q1 24 | $166.0M | $562.5M |
株主資本CSWLNTH
| Q4 25 | $1.1B | $1.1B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $1.1B | $1.2B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.0B | $1.1B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $650.2M | $1.0B | ||
| Q1 24 | $615.7M | $945.5M |
総資産CSWLNTH
| Q4 25 | $2.3B | $2.2B | ||
| Q3 25 | $1.5B | $2.3B | ||
| Q2 25 | $1.5B | $2.1B | ||
| Q1 25 | $1.4B | $2.1B | ||
| Q4 24 | $1.4B | $2.0B | ||
| Q3 24 | $1.4B | $2.0B | ||
| Q2 24 | $1.1B | $1.9B | ||
| Q1 24 | $1.0B | $1.8B |
負債/資本比率CSWLNTH
| Q4 25 | — | 0.52× | ||
| Q3 25 | — | 0.51× | ||
| Q2 25 | — | 0.49× | ||
| Q1 25 | 0.75× | 0.49× | ||
| Q4 24 | — | 0.52× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.55× | ||
| Q1 24 | 0.27× | 0.59× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $28.9M | $90.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $22.7M | $81.4M |
| FCFマージンFCF / 売上 | 9.8% | 20.0% |
| 設備投資強度設備投資 / 売上 | 2.6% | 2.2% |
| キャッシュ転換率営業CF / 純利益 | 2.81× | 1.67× |
| 直近12ヶ月FCF直近4四半期 | $162.0M | $354.1M |
8四半期トレンド — 暦四半期で整列
営業キャッシュフローCSWLNTH
| Q4 25 | $28.9M | $90.2M | ||
| Q3 25 | $61.8M | $105.3M | ||
| Q2 25 | $60.6M | $87.1M | ||
| Q1 25 | $27.3M | $107.6M | ||
| Q4 24 | $11.6M | $157.7M | ||
| Q3 24 | $66.8M | $175.1M | ||
| Q2 24 | $62.7M | $84.7M | ||
| Q1 24 | $22.4M | $127.2M |
フリーキャッシュフローCSWLNTH
| Q4 25 | $22.7M | $81.4M | ||
| Q3 25 | $58.7M | $94.7M | ||
| Q2 25 | $57.7M | $79.1M | ||
| Q1 25 | $22.8M | $98.8M | ||
| Q4 24 | $8.5M | $141.4M | ||
| Q3 24 | $61.3M | $159.3M | ||
| Q2 24 | $59.6M | $73.5M | ||
| Q1 24 | $17.5M | $119.0M |
FCFマージンCSWLNTH
| Q4 25 | 9.8% | 20.0% | ||
| Q3 25 | 21.2% | 24.7% | ||
| Q2 25 | 21.9% | 20.9% | ||
| Q1 25 | 9.9% | 26.5% | ||
| Q4 24 | 4.4% | 36.1% | ||
| Q3 24 | 26.9% | 42.0% | ||
| Q2 24 | 26.3% | 18.7% | ||
| Q1 24 | 8.3% | 32.2% |
設備投資強度CSWLNTH
| Q4 25 | 2.6% | 2.2% | ||
| Q3 25 | 1.1% | 2.8% | ||
| Q2 25 | 1.1% | 2.1% | ||
| Q1 25 | 2.0% | 2.3% | ||
| Q4 24 | 1.6% | 4.2% | ||
| Q3 24 | 2.4% | 4.2% | ||
| Q2 24 | 1.4% | 2.8% | ||
| Q1 24 | 2.3% | 2.2% |
キャッシュ転換率CSWLNTH
| Q4 25 | 2.81× | 1.67× | ||
| Q3 25 | 1.52× | 3.79× | ||
| Q2 25 | 1.48× | 1.11× | ||
| Q1 25 | 0.78× | 1.47× | ||
| Q4 24 | 0.43× | — | ||
| Q3 24 | 1.85× | 1.34× | ||
| Q2 24 | 1.62× | 1.36× | ||
| Q1 24 | 0.71× | 0.97× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CSW
| Contractor Solutions Segment | $166.3M | 71% |
| Specialized Reliability Solutions Segment | $38.2M | 16% |
| Engineered Building Solutions Segment | $28.5M | 12% |
LNTH
| Radiopharmaceutical Oncology | $240.2M | 59% |
| Definity | $85.3M | 21% |
| Strategic Partnerships And Other | $23.3M | 6% |
| Techne Lite | $21.0M | 5% |
| Licenseand Royalty Revenues | $17.4M | 4% |
| Other | $13.6M | 3% |
| Other Precision Diagnostics | $5.9M | 1% |
